Tech Company Inital Public Offerings
PMV Pharmaceuticals IPO
PMV Pharmaceuticals, operating out of Cranbury, had an IPO event on 9/24/2020.
Transaction Overview
Company Name
Announced On
9/24/2020
Transaction Type
IPO
Amount
$211,770,000
Proceeds Purpose
Management says it will use the net proceeds from the IPO as follows:to fund the Phase 1/2 development of PC14586;to support the development of our R273H program, including lead optimization and IND-enabling studies;or the development of our pipeline discovery programs; andthe remaining proceeds, if any, for other research and development opportunities, working capital and general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
8 Clarke Dr. 3
Cranbury, NJ 08512
USA
Cranbury, NJ 08512
USA
Phone
Undisclosed
Website
Email Address
Overview
PMV Pharmaceuticals (Nasdaq: PMVP) is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV combines unique biological understanding with pharmaceutical development focus.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Mack
Chief Medical Officer
Leila Alland
Chief Operating Officer
Winston Kung
Vice President
Thomas Davis
Vice President
Melissa Dumble
Vice President
Binh Vu
VP - Regulatory Affairs
Deepika Jalota
Browse more venture capital transactions:
Prev: 9/24/2020: Silverback Therapeutics venture capital transaction
Next: 9/24/2020: Libra Therapeutics venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs